REG - Oxford Biomedica PLC - Oxford Biomedica Updates Lentiviral Agreement

Oxford BioMedicaAnnouncement

13/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211213:nRSM3585Va&default-theme=true

RNS Number : 3585V  Oxford Biomedica PLC  13 December 2021

 

The information contained within this announcement is deemed by the Group to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 (as it forms part of domestic law by virtue of the European
Union (Withdrawal) Act 2018). Upon the publication of this announcement via
the Regulatory Information Service, this inside information is now considered
to be in the public domain.

 

 

Oxford Biomedica updates and extends Commercial Supply Agreement for
Manufacture of Lentiviral Vectors

 

 

Oxford, UK - 13 December, 2021: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Group"), a leading gene and cell therapy group, announced
today that it has agreed an extension and update to its commercial supply
Agreement with Novartis for the manufacture of lentiviral vectors for several
Novartis CAR-T products.

 

Oxford Biomedica initially licensed its LentiVector(®) platform to Novartis
in the field of CAR-T in October 2014
(https://otp.investis.com/clients/uk/oxford_biomed1/rns/regulatory-story.aspx?cid=544&newsid=450835)
, followed by a 5 year commercial supply agreement signed by Oxford Biomedica
and Novartis in December 2019
(https://otp.investis.com/clients/uk/oxford_biomed1/rns/regulatory-story.aspx?cid=544&newsid=1353964)
. Under the terms of the updated agreement announced today, the parties have
extended the terms of the commercial supply agreement to the end of 2028 and
Oxford Biomedica has regained the rights to its LentiVector® platform
relating to three CAR-T targets, including CD19 targeted therapies. The Group
now has the right to work with potential pharmaceutical and biotech partners
other than Novartis across all CAR-T targets.

 

In addition, under the terms of the new agreement Novartis has been granted
additional flexibility in ordering of GMP batches across Oxford Biomedica's
multiple GMP facilities but will no longer have a minimum order commitment.
This is expected to result in a mid-single digit £ million reduction in
previously guided FY21 revenues. The Group continues to work on multiple CAR-T
programs with Novartis, including Kymriah®, as well as a broad number of
development opportunities on which the Group earns manufacturing revenues,
process development fees and royalties on net sales.

 

 

John Dawson, Chief Executive Officer of Oxford Biomedica, said:

"This news today is an example of Oxford Biomedica seeking to adapt to
customer needs over time, our strength as a long-term partner and our goal to
unlock value and build scale across the Group.

 

"We have enjoyed a strategic partnership with Novartis since 2014 and are
excited to announce this updated supply agreement which provides both
companies with greater flexibility in GMP supply of vector for Kymriah and
other pipeline products and allows us to react to the rapidly growing dynamics
of the commercial CAR-T sector.

 

"In return, we are very pleased to have regained the ability to license our
LentiVector® platform across all CAR-T targets, maximising our ability to
serve a larger proportion of the growing market for lentiviral vectors."

 

-Ends-

 

 

Enquiries:

 

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com

 

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

 

Consilium Strategic Communications: T: +44 (0)20 3709 5700

 

Mary-Jane Elliott / Matthew Neal

 

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell
therapy group focused on developing life changing treatments for serious
diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a
sector leading lentiviral vector delivery platform (LentiVector®), which the
Group leverages to develop in vivo and ex vivo products both in-house and with
partners. The Group has created a valuable proprietary portfolio of gene and
cell therapy product candidates in the areas of oncology, CNS disorders and
liver diseases. The Group has also entered into a number of partnerships,
including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard
Therapeutics, Santen, Beam Therapeutics and Boehringer Ingelheim, through
which it has long-term economic interests in other potential gene and cell
therapy products. Additionally, the Group has signed a 3-year master supply
and development agreement with AstraZeneca for large-scale manufacturing of
the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is
based across several locations in Oxfordshire, UK and employs more than 740
people. Further information is available at www.oxb.com (http://www.oxb.com)
 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDGBDDCBBDGBD